Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study

The present study aimed to determine the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) without a loading dose in the real-world setting. The PROBE study (Pro Re Nata Brolucizumab for Exudative AMD) is a retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilgic, Alper, Kodjikian, Laurent, Srivastava, Samaresh, Dwivedi, Shyamal, Banker, Alay S, Abukashabah, Amro, Sudhalkar, Aditya, Mathis, Thibaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465009/
https://www.ncbi.nlm.nih.gov/pubmed/34575264
http://dx.doi.org/10.3390/jcm10184153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465009/
https://www.ncbi.nlm.nih.gov/pubmed/34575264
http://dx.doi.org/10.3390/jcm10184153

Ejemplares similares